Kovalevska L, Zadvornyj T, Lukianova N, Kashuba E
RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine.
Exp Oncol. 2022 May;44(1):47-51. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-1.17380.
The evolution of research on the therapy of prostate cancer (PC) depends on a study of molecules that are involved in the progression of this disease. Nevertheless, there is a need for additional biomarkers that would help to refine the molecular profile of PC and propose the personalized therapeutic approach.
To study differential expression patterns of the AIP, UCKL1, and PKN1 genes in blood sera and tumor tissue of patients with PC with different Gleason scores.
The total extracellular RNA was isolated from blood sera of 44 PC patients and 4 healthy donors. cDNAs were synthesized and quantitative polymerase chain reaction (qPCR) was performed. Immunohistochemical study of the UCKL, AIP and PKN1 proteins was performed on deparaffinized sections of tumors. The study was supplemented by a bioinformatic analysis of the publicly available databases.
The UCKL1, AIP, PKN1 genes were overexpressed at the mRNA level in blood sera of PC patients, compared to healthy donors. Extracellular mRNA levels of AIP and UCKL-1 were 100-1000-fold increased in all PC samples compared to the healthy donors but without significant inequality between the groups of PC cases differing by the Gleason score. The highest levels were detected in the samples from PC patients with the Gleason score > 9. The PKN1 expression was higher in PC patients compared with healthy donors but without significant difference between the groups.
From the three chosen genes, AIP and UCKL1 showed similar pattern of expression assessed either by extracellular mRNA levels in patient sera or the protein in PC tissues. AIP was up to 1000-fold increased in all PC samples, compared to the healthy donors, with the highest levels in PC cases with Gleason score > 9. Expression levels of the AIP and UCKL1 genes in the PC patient sera may be used as an additional criterion for prognosis of tumor progression.
前列腺癌（PC）治疗研究的进展依赖于对参与该疾病进展的分子的研究。然而，仍需要更多的生物标志物来完善PC的分子特征并提出个性化治疗方案。
研究不同Gleason评分的PC患者血清和肿瘤组织中AIP、UCKL1和PKN1基因的差异表达模式。
从44例PC患者和4例健康供体的血清中分离总细胞外RNA。合成cDNA并进行定量聚合酶链反应（qPCR）。对肿瘤石蜡切片进行UCKL、AIP和PKN1蛋白的免疫组织化学研究。该研究通过对公开可用数据库的生物信息学分析进行补充。
与健康供体相比，PC患者血清中UCKL1、AIP、PKN1基因在mRNA水平上过度表达。与健康供体相比，所有PC样本中AIP和UCKL-1的细胞外mRNA水平增加了100-1000倍，但不同Gleason评分的PC病例组之间无显著差异。在Gleason评分>9的PC患者样本中检测到最高水平。与健康供体相比，PC患者中PKN1表达更高，但组间无显著差异。
从所选的三个基因来看，如果通过患者血清中的细胞外mRNA水平或PC组织中的蛋白质来评估，AIP和UCKL1显示出相似的表达模式。与健康供体相比，所有PC样本中AIP增加了1000倍，在Gleason评分>9的PC病例中水平最高。PC患者血清中AIP和UCKL1基因的表达水平可作为肿瘤进展预后的额外标准。
